XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
E. Morrow “Morrey” Atkinson III
EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
8/22/20234/30/2024
9,224(2)
Reshma Kewalramani
President, Chief Executive Officer and Director
8/11/20238/15/2024
27,330
Jeffrey M. Leiden
Executive Chairman
8/4/20235/15/2025
40,454(2)
Bastiano Sanna
EVP, Chief of Cell and Genetic Therapies
8/25/20238/9/2024
32,833(2)
Charles F. Wagner, Jr.
EVP, Chief Financial Officer
8/18/20238/9/2024
6,000
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
E. Morrow "Morrey" Atkinson III [Member]    
Trading Arrangements, by Individual    
Name E. Morrow “Morrey” Atkinson III  
Title EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/22/2023  
Arrangement Duration 252 days  
Aggregate Available 9,224 9,224
Reshma Kewalramani [Member]    
Trading Arrangements, by Individual    
Name Reshma Kewalramani  
Title President, Chief Executive Officer and Director  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/11/2023  
Arrangement Duration 370 days  
Aggregate Available 27,330 27,330
Jeffrey M. Leiden [Member]    
Trading Arrangements, by Individual    
Name Jeffrey M. Leiden  
Title Executive Chairman  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/4/2023  
Arrangement Duration 650 days  
Aggregate Available 40,454 40,454
Bastiano Sanna [Member]    
Trading Arrangements, by Individual    
Name Bastiano Sanna  
Title EVP, Chief of Cell and Genetic Therapies  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/25/2023  
Arrangement Duration 350 days  
Aggregate Available 32,833 32,833
Charles F. Wagner, Jr. [Member]    
Trading Arrangements, by Individual    
Name Charles F. Wagner, Jr.  
Title EVP, Chief Financial Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/18/2023  
Arrangement Duration 357 days  
Aggregate Available 6,000 6,000